GP breast cancer guidelines ‘miss 95% of young women who will get disease’

By the Editorial Team · Tuesday, August 4, 2026

Researchers from the University of Cambridge and the Institute of Cancer Research found that current breast cancer referral guidelines in England miss up to 95% of women under 50 who will develop the disease within a decade. Their study highlights the need for updated criteria incorporating broader risk factors, such as those in the Boadicea tool, to improve early detection and prevention despite challenges in implementation.

Research from the University of Cambridge and the Institute of Cancer Research (ICR), London, indicates that current breast cancer referral guidelines used by general practitioners in England may fail to identify up to 95% of women under 50 who will develop the disease within 10 years. The findings, published in the British Journal of Cancer, suggest that existing criteria, developed by the National Institute for Health and Care Excellence (Nice), overlook the vast majority of younger women at elevated risk, prompting calls for a review of the guidelines.

Breast cancer remains the most common cancer among women globally and is a leading cause of death in women under 50. Early detection of high-risk patients can enable additional screening or preventive interventions, potentially improving outcomes. In England, GPs typically refer women for specialist assessment based on family history and criteria recommended by Nice.

The new study compared the current Nice referral standards with a novel risk assessment tool called Boadicea, developed by Cambridge researchers with funding from Cancer Research UK. Unlike the NICE model, Boadicea incorporates a broader range of risk factors including reproductive history, lifestyle choices, and genetic information. The researchers found that Boadicea identified eight times more women under age 50 who would go on to develop breast cancer than the existing guidelines.

A key factor behind the limitations of the current criteria is the reliance on family history of breast cancer; 73% of women under 50 who develop the disease within 10 years do not have a known family history. Dr. Juliet Usher-Smith of the University of Cambridge emphasized the need for improved risk identification, stating that early intervention offers more treatment options and even opportunities for prevention.

Professor Montserrat García-Closas of the ICR cautioned that while more comprehensive assessments could better identify at-risk women, they also present challenges. “There will be a balance to strike,” she said, noting that the simplicity of the Nice criteria facilitates easier implementation, whereas fuller risk evaluations including genetic testing may impose significant resource demands. Decisions will need to weigh these practical considerations against the benefits and potential harms of more precise risk classification.

Dr. Simon Vincent, chief scientific officer of Breast Cancer Now, which supported the study, underscored the potential benefits of improved risk identification. He stressed that any updates to referral protocols should be accompanied by adequate investment in family history services to ensure effective and equitable application across the NHS.

A spokesperson for Nice acknowledged the study’s findings and the promise of multifactorial risk models but stated that current evidence does not justify changes to existing familial breast cancer guidelines at present. They affirmed Nice’s ongoing commitment to reviewing new data and considering updates as more information on feasibility and clinical outcomes becomes available.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.